Biotechnology - UCB

Filter

Current filters:

UCB

Popular Filters

UCB invites scientists to access its new cutting-edge technology platform

UCB invites scientists to access its new cutting-edge technology platform

28-04-2014

The UK subsidiary of Belgium’s leading pharma company UCB, which at the end of last year completed…

BiotechnologyResearchUCB

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

Oncodesign and UCB enter into collaboration for development of Nanocyclix in neurodegenerative diseases

13-11-2013

French drug discovery company Oncodesign has entered into a research collaboration and exclusive license…

BiotechnologyEuropeLicensingNeurologicalOncodesignUCB

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

UCB and Amgen not to progress development of romosozumab for fracture healing

13-02-2013

Belgium's leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq:…

AmgenAnti-Arthritics/RheumaticsBiotechnologyPharmaceuticalResearchromosozumabUCB

UCB inaugurates new biotech plant

16-09-2012

In preparation for the growing demand for biological medicines, Belgian drugmaker UCB (Euronext Brussels:…

BiotechnologyEuropePharmaceuticalProductionUCB

Biotie assets available for partnering; update on tozadenant

08-07-2012

Finland-based biotech firm Biotie Therapies' (OMX: BTH1V) retention of SYN120 rights after Roche decided…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckNeurologicalResearchSelincroSYN120tozadenantUCB

UCB and Domainex elaborate on cancer drug target collaboration

12-03-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) and Domainex, a UK-based drug discovery company, have…

BiotechnologyDomainexOncologyPharmaceuticalResearchUCB

Back to top